Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)

NCT04541043 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
119
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Calliditas Therapeutics AB